 |
answer text |
<p>The National Institute for Health and Care Excellence (NICE) is the independent
body responsible for developing authoritative, evidence-based guidance for the National
Health Service on whether drugs and other treatments represent an effective use of
NHS resources.</p><p>NICE is currently developing technology appraisal guidance on
the use of ocrelizumab for treating primary progressive multiple sclerosis, with final
guidance expected in June 2019. NHS England and Roche have now reached a commercial
agreement and on 9 May NICE published final draft guidance which recommended ocrelizumab
within its marketing authorisation, as an option for treating early primary progressive
multiple sclerosis with imaging features characteristic of inflammatory activity in
adults. Ocrelizumab will now be routinely available for eligible adults.</p><p> </p>
|
 |
